Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study

Despoina Kalapanida; Flora Zagouri; Maria Gazouli; Eleni Zografos; Constantine Dimitrakakis; Spyridon Marinopoulos; Aris Giannos; Theodoros N. Sergentanis; Efstathios Kastritis; Evangelos Terpos; Meletios-Athanasios Dimopoulos

doi:10.18632/oncotarget.26385

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study

Despoina Kalapanida, Flora Zagouri _, Maria Gazouli, Eleni Zografos, Constantine Dimitrakakis, Spyridon Marinopoulos, Aris Giannos, Theodoros N. Sergentanis, Efstathios Kastritis, Evangelos Terpos and Meletios-Athanasios Dimopoulos

PDF | HTML | How to cite

Oncotarget. 2018; 9:36906-36913. https://doi.org/10.18632/oncotarget.26385

Metrics: PDF 1294 views | HTML 1880 views | ?

Abstract

Despoina Kalapanida1, Flora Zagouri1, Maria Gazouli2,3, Eleni Zografos2,3, Constantine Dimitrakakis4, Spyridon Marinopoulos4, Aris Giannos4, Theodoros N. Sergentanis1, Efstathios Kastritis1, Evangelos Terpos1 and Meletios-Athanasios Dimopoulos1

1Department of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Athens, Greece

2Department of Basic Medical Sciences, Laboratory of Biology, University of Athens School of Medicine, Athens, Greece

3Laboratory of Cell and Gene Therapy, Biomedical Research Foundation of the Academy of Athens, Athens, Greece

4Department of Obstetrics and Gynaecology, Alexandra Hospital, Medical school, University of Athens, Athens, Greece

Correspondence to:

Flora Zagouri, email: [email protected]

Keywords: SNPs; pre-miR-34a; miRNA; triple negative breast cancer; biomarker

Received: September 13, 2018 Accepted: November 03, 2018 Published: December 11, 2018

ABSTRACT

Aim: The purpose of this study is to evaluate the role of pre-miR34a rs72631823 as potential risk factor and/or prognostic marker in patients with triple negative breast cancer.

Methods: 114 samples of DNA from paraffin embedded breast normal tissues of patients with triple negative breast cancer and 124 samples of healthy controls were collected and analyzed for pre-miR34a rs72631823 polymorphism.

Results: Pre-miR34a rs72631823 A allele was associated with increased TNBC risk both in univariate and multivariate analysis. The number of pre-miR34a rs72631823 AA subjects was very small and the association did not reach significance (p = 0.176, Fisher’s exact test). The examined polymorphism was not associated with overall survival at the univariate or multivariate Cox regression analysis (adjusted HR = 1.60, 95%CI: 0.64–3.96 for miR34 rs72631823 GA/AA vs. GG).

Conclusion: Our case-control study suggests that pre-miR34a rs72631823 A allele is associated with increased triple negative breast cancer risk.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26385

Publication Alerts

Research Papers:

Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study

Abstract